Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
February 07 2018 - 4:30PM
Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a
biopharmaceutical company focused on the development and
commercialization of innovative therapeutics to treat orphan
autoimmune and inflammatory diseases, today announced that the
Company's management will present an overview of the Company and
host investor meetings at the Leerink Partners 7th Annual Global
Healthcare Conference.
Date: Thursday, February 15, 2018Time: 11:00
a.m. ETPlace: Lotte New York Palace, New York
A live webcast of the presentation can be
accessed by visiting ‘Events’ in the Investors Section on the
Company's website at www.akaritx.com. An archived replay of the
webcast will be available for 60 days on the Company's website
after the conference.
About Akari TherapeuticsAkari
is a biopharmaceutical company focused on developing inhibitors of
acute and chronic inflammation, specifically the complement system,
the eicosanoid system and the bioamine system for the treatment of
rare and orphan diseases, in particular those where the complement
system or leukotrienes or both complement and leukotrienes together
play a primary role in disease progression. Akari's lead drug
candidate Coversin is a C5 complement inhibitor currently being
evaluated in paroxysmal nocturnal hemoglobinuria (PNH) and atypical
hemolytic uremic syndrome (aHUS). In addition to its C5 inhibitory
activity, Coversin independently and specifically inhibits
leukotriene B4 (LTB4) activity. Akari intends to evaluate Coversin
in two conditions, the skin and eye diseases bullous pemphigoid and
atopic keratoconjunctivitis, where the dual action of Coversin on
both C5 and LTB4 may be beneficial. Akari is also developing other
tick derived proteins, including long acting versions.
Cautionary Note Regarding
Forward-Looking StatementsCertain statements in this press
release constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected in
or suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control. Such risks and
uncertainties for our company include, but are not limited to:
needs for additional capital to fund our operations, an inability
or delay in obtaining required regulatory approvals for Coversin
and any other product candidates, which may result in unexpected
cost expenditures; risks inherent in drug development in general;
uncertainties in obtaining successful clinical results for Coversin
and any other product candidates and unexpected costs that may
result therefrom; failure to realize any value of Coversin and any
other product candidates developed and being developed in light of
inherent risks and difficulties involved in successfully bringing
product candidates to market; inability to develop new product
candidates and support existing product candidates; the approval by
the FDA and EMA and any other similar foreign regulatory
authorities of other competing or superior products brought to
market; risks resulting from unforeseen side effects; risk that the
market for Coversin may not be as large as expected; risks
associated with the putative shareholder class action and SEC
requests for information; inability to obtain, maintain and enforce
patents and other intellectual property rights or the unexpected
costs associated with such enforcement or litigation; inability to
obtain and maintain commercial manufacturing arrangements with
third party manufacturers or establish commercial scale
manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party
manufacturers on whom the company depends; our inability to obtain
additional capital on acceptable terms, or at all; unexpected cost
increases and pricing pressures; uncertainties of cash flows and
inability to meet working capital needs; and risks and other risk
factors detailed in our public filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 20-F filed
on March 31, 2017 and in our Report on Form 6-K filed with the SEC
on October 17, 2017. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release and we undertake no obligation to update or revise any of
these statements to reflect events or circumstances occurring after
this press release. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
For more information
Investor Contact:
Peter VozzoWestwicke Partners(443)
213-0505peter.vozzo@westwicke.com
Media Contact:
Mary-Jane Elliott / Sukaina Virji / Nicholas
BrownConsilium Strategic Communications+44 (0)20 3709
5700Akari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024